BD Invests $100 Million in Nebraska Plant to Expand Insulin Syringe Manufacturing

Sep 22, 2016

FRANKLIN LAKES, N.J., Sept. 22, 2016 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it is investing $100 million in its Holdrege, Neb. facility to expand capacity for its insulin syringe manufacturing operations.

The investment will be used for new technology and manufacturing equipment to expand capacity for BD insulin syringes. BD already produces more than 2 billion insulin syringes each year, which averages to be more than 250,000 syringes per hour.

"About 40 percent of people with diabetes who inject insulin use syringes as part of their diabetes management regimen," said Ken Miller, worldwide president of Diabetes Care for BD. "This investment will provide benefits to this diabetes population and underscores our commitment to supply high-quality, industry-leading insulin syringes to patients."

BD began operations in Holdrege in 1966 in a 12,000 square foot building with 66 associates. Today, the facility has grown to 350,000 square feet with more than 650 associates manufacturing 20 different BD products. BD is the largest employer in Phelps County. Across Nebraska, BD employs more than 2,500 associates in four manufacturing facilities in Holdrege, Broken Bow and two in Columbus.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

For more information on BD, please visit

Troy Kirkpatrick

858 617 2361
Email Troy

Monique N. Dolecki

201 847 5378

Back to News Releases

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.